...
首页> 外文期刊>OncoTargets and therapy >Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells
【24h】

Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells

机译:NSD3(WHSC1L1)的下调通过ERK1 / 2失活和降低大肠癌细胞中CAPG表达来抑制细胞增殖和迁移

获取原文

摘要

Purpose: NSD3 (WHSC1L1) is a protein lysine methyltransferase that is recurrently amplified (8p11.23) in several cancer types, and its upregulation is involved in tumor cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT). We aimed to evaluate its potential function as an oncogenic force in colorectal cancer (CRC), and to elucidate relevant mechanisms of its oncogenic activity. Materials?and methods: NSD3 levels were analyzed in human CRC and adjacent normal tissues or cells by Western blot analysis and RT-qPCR. Expression levels of the proteins were detected by Western blot analysis and RT-qPCR. Results: NSD3 was significantly upregulated in both CRC tissues and cell lines. Knockdown of NSD3 expression resulted in significant decreases in CRC cell proliferation, migration, and EMT process marker proteins vimentin, simultaneously reducing E-cadherin and N-cadherin expression. The opposite results were observed when NSD3 was overexpressed. Additionally, overexpressing of NSD3 dramatically activated the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway and enhanced actin-capping protein (CAPG) expression. Furthermore, the proliferation and migration abilities evidently facilitated by pcDNA3.1(+) expression vector containing full-length CDS of NSD3 (pcDNA3.1(+)-NSD3, or NSD3) were partially decreased after incubation with ERK1/2 signaling pathway inhibitor (PD98059) and/or specific siRNA against CAPG (siCAPG) in SW480 and HT-29 CRC cells. Conclusion: NSD3 overexpression stimulated CRC cell proliferation and migration through targeting the ERK1/2 signaling pathway and downstream CAPG. Thus, NSD3 could serve as a promising target for anticancer drug development for patients with CRC.
机译:目的:NSD3(WHSC1L1)是一种蛋白质赖氨酸甲基转移酶,在几种癌症类型中均会被反复扩增(8p11.23),其上调与肿瘤细胞的增殖,转移和上皮-间质转化(EMT)有关。我们旨在评估其作为结肠直肠癌(CRC)致癌力的潜在功能,并阐明其致癌活性的相关机制。材料和方法:通过蛋白质印迹分析和RT-qPCR分析人CRC和邻近正常组织或细胞中NSD3的水平。通过蛋白质印迹分析和RT-qPCR检测蛋白质的表达水平。结果:NSD3在CRC组织和细胞系中均显着上调。降低NSD3表达可导致CRC细胞增殖,迁移和EMT过程标记蛋白波形蛋白显着降低,同时降低E-钙粘蛋白和N-钙粘蛋白的表达。当NSD3过表达时,观察到相反的结果。此外,NSD3的过表达极大地激活了细胞外信号调节激酶1/2(ERK1 / 2)信号通路并增强了肌动蛋白封端蛋白(CAPG)的表达。此外,与ERK1 / 2信号通路抑制剂一起孵育后,含有NSD3全长CDS的pcDNA3.1(+)表达载体明显促进了增殖和迁移能力(pcDNA3.1(+)-NSD3或NSD3)。 (PD98059)和/或SW480和HT-29 CRC细胞中针对CAPG的特异性siRNA(siCAPG)。结论:NSD3过表达通过靶向ERK1 / 2信号通路和下游CAPG刺激CRC细胞增殖和迁移。因此,NSD3可以作为CRC患者抗癌药物开发的有希望的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号